 <h1>Doripenem Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to doripenem: intravenous powder for suspension</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, doripenem may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking doripenem:</p><p>
<i>More common</i>
</p><ul>
<li>Bluish color</li>
<li>diarrhea</li>
<li>pain, tenderness, or swelling of the foot or leg</li>
<li>pale skin</li>
<li>troubled breathing with exertion</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Abdominal or stomach cramps, pain, or tenderness</li>
<li>bloody urine</li>
<li>decreased frequency or amount of urine</li>
<li>fever</li>
<li>increased blood pressure</li>
<li>increased thirst</li>
<li>itching or pain of the vagina or genital area</li>
<li>loss of appetite</li>
<li>lower back or side pain</li>
<li>nausea or vomiting</li>
<li>sore mouth or tongue</li>
<li>swelling of the face, fingers, or lower legs</li>
<li>thick, white vaginal discharge with mild or no odor</li>
<li>troubled breathing</li>
<li>watery and severe diarrhea, which may also be bloody</li>
<li>weight gain</li>
<li>white patches in the mouth or on the tongue</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>chills</li>
<li>cough</li>
<li>difficulty with swallowing or sore throat</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>itching</li>
<li>joint or muscle pain</li>
<li>loss of bladder control</li>
<li>muscle spasm or jerking of extremities</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>skin rash or hives</li>
<li>sores, ulcers, or white spots in the mouth or on the lips</li>
<li>sudden loss of consciousness</li>
<li>tightness in the chest</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of doripenem may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Headache</li>
</ul><p>
<!-- end intravenous powder for suspension --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to doripenem: intravenous powder for injection</i></p><h3>General</h3><p>In 5 clinical trials, 1338 adult patients received this drug.  The most common side effects were anemia, headache, nausea, diarrhea, rash, elevated hepatic enzymes, and phlebitis.  During clinical studies, this drug was discontinued due to side effects in 4.1% of patients.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 16%)</p>
<p><b>Frequency not reported</b>: Dizziness</p>
<p><b>Postmarketing reports</b>: Seizure<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 12%), diarrhea (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Oral candidiasis</p>
<p><b>Uncommon</b> (0.1% to 1%): Clostridium difficile colitis</p>
<p><b>Frequency not reported</b>: Constipation, abdominal pain, dyspepsia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity reactions</p>
<p><b>Postmarketing reports</b>: Anaphylaxis<sup>[Ref]</sup></p><p>Serious and sometimes fatal hypersensitivity (anaphylactic) reactions have been reported with beta-lactams.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Anemia</p>
<p><b>Postmarketing reports</b>: Neutropenia, leukopenia, thrombocytopenia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Phlebitis</p>
<p><b>Frequency not reported</b>: Atrial fibrillation, atrial flutter, hypertension, hypotension<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Elevated hepatic enzymes also included ALT or AST at or below the upper limit of normal (ULN) at baseline increasing to greater than 5 times ULN at end of therapy.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Elevated hepatic enzymes (includes elevated ALT, elevated AST, elevated transaminases)</p>
<p><b>Frequency not reported</b>: Cholestasis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>The incidence of rash was higher in patients receiving doses greater than the approved dose compared to those receiving the approved dose.  The rash resolved within 10 days after this drug was stopped.</p>
<p></p>
<p>Serious skin reactions have been reported with beta-lactams.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Rash, pruritus</p>
<p><b>Frequency not reported</b>: Erythema, macular/papular eruptions, bullous dermatitis, urticaria, erythema multiforme, allergic dermatitis, decubitus ulcer</p>
<p><b>Postmarketing reports</b>: Stevens-Johnson syndrome, toxic epidermal necrolysis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Vulvomycotic infection</p>
<p><b>Frequency not reported</b>: Urinary tract infection, asymptomatic bacteriuria<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Pneumonitis has been reported when this drug was administered via inhalation.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Pneumonitis, pneumonia, pleural effusion, dyspnea</p>
<p><b>Postmarketing reports</b>: Interstitial pneumonia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Postmarketing reports</b>: Renal impairment/renal failure<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hypokalemia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Pyrexia, peripheral edema<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Insomnia, anxiety<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Doripenem (Doribax)--a new parenteral carbapenem." Med Lett Drugs Ther 50 (2008): 5-7</p><p id="ref_2">2. Chastre J,  Wunderink R,  Prokocimer P,  Lee M,  Kaniga K,  Friedland I "Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study." Crit Care Med 36 (2008): 1089-96</p><p id="ref_3">3. Cerner Multum,  Inc "Malaysia product information." O 0 (2015):</p><p id="ref_4">4. "Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical, Raritan, NJ. </p><p id="ref_5">5. EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&amp;mid."  </p><p id="ref_6">6. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_7">7. "Doripenem (doribax)--a new parenteral carbapenem." Obstet Gynecol 111 (2008): 1206-7</p></div>
<div class="more-resources" id="moreResources">
<h2>More about doripenem</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>1 Review</li>
<li>Drug class: carbapenems</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Doribax</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Urinary Tract Infection</li>
<li>Intraabdominal Infection</li>
<li>Kidney Infections</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to doripenem: intravenous powder for injection</i></p><h3>General</h3><p>In 5 clinical trials, 1338 adult patients received this drug.  The most common side effects were anemia, headache, nausea, diarrhea, rash, elevated hepatic enzymes, and phlebitis.  During clinical studies, this drug was discontinued due to side effects in 4.1% of patients.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 16%)</p><p><b>Frequency not reported</b>: Dizziness</p><p><b>Postmarketing reports</b>: Seizure<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 12%), diarrhea (up to 12%)</p><p><b>Common</b> (1% to 10%): Oral candidiasis</p><p><b>Uncommon</b> (0.1% to 1%): Clostridium difficile colitis</p><p><b>Frequency not reported</b>: Constipation, abdominal pain, dyspepsia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Hypersensitivity reactions</p><p><b>Postmarketing reports</b>: Anaphylaxis<sup>[Ref]</sup></p><p>Serious and sometimes fatal hypersensitivity (anaphylactic) reactions have been reported with beta-lactams.<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Anemia</p><p><b>Postmarketing reports</b>: Neutropenia, leukopenia, thrombocytopenia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Phlebitis</p><p><b>Frequency not reported</b>: Atrial fibrillation, atrial flutter, hypertension, hypotension<sup>[Ref]</sup></p><h3>Hepatic</h3><p>Elevated hepatic enzymes also included ALT or AST at or below the upper limit of normal (ULN) at baseline increasing to greater than 5 times ULN at end of therapy.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Elevated hepatic enzymes (includes elevated ALT, elevated AST, elevated transaminases)</p><p><b>Frequency not reported</b>: Cholestasis<sup>[Ref]</sup></p><h3>Dermatologic</h3><p>The incidence of rash was higher in patients receiving doses greater than the approved dose compared to those receiving the approved dose.  The rash resolved within 10 days after this drug was stopped.</p><p></p><p>Serious skin reactions have been reported with beta-lactams.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Rash, pruritus</p><p><b>Frequency not reported</b>: Erythema, macular/papular eruptions, bullous dermatitis, urticaria, erythema multiforme, allergic dermatitis, decubitus ulcer</p><p><b>Postmarketing reports</b>: Stevens-Johnson syndrome, toxic epidermal necrolysis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Vulvomycotic infection</p><p><b>Frequency not reported</b>: Urinary tract infection, asymptomatic bacteriuria<sup>[Ref]</sup></p><h3>Respiratory</h3><p>Pneumonitis has been reported when this drug was administered via inhalation.<sup>[Ref]</sup></p><p><b>Frequency not reported</b>: Pneumonitis, pneumonia, pleural effusion, dyspnea</p><p><b>Postmarketing reports</b>: Interstitial pneumonia<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Postmarketing reports</b>: Renal impairment/renal failure<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hypokalemia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Frequency not reported</b>: Pyrexia, peripheral edema<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Frequency not reported</b>: Insomnia, anxiety<sup>[Ref]</sup></p><p id="ref_1">1. "Doripenem (Doribax)--a new parenteral carbapenem." Med Lett Drugs Ther 50 (2008): 5-7</p><p id="ref_2">2. Chastre J,  Wunderink R,  Prokocimer P,  Lee M,  Kaniga K,  Friedland I "Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study." Crit Care Med 36 (2008): 1089-96</p><p id="ref_3">3. Cerner Multum,  Inc "Malaysia product information." O 0 (2015):</p><p id="ref_4">4. "Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical, Raritan, NJ. </p><p id="ref_5">5. EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&amp;mid."  </p><p id="ref_6">6. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_7">7. "Doripenem (doribax)--a new parenteral carbapenem." Obstet Gynecol 111 (2008): 1206-7</p><h2>More about doripenem</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>1 Review</li>
<li>Drug class: carbapenems</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Advanced Reading</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +2 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Urinary Tract Infection</li>
<li>Intraabdominal Infection</li>
<li>Kidney Infections</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>